Investors Overview
We’re Delivering the Promise of Healthier Lives.
Our Company
Corporate Profile
CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
Stock Today
Headquarters
CURE Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone:
Fax:
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Cure Pharmaceutical
Our Investor Presentation
Media
Recent Videos
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Press Releases
CURE Pharmaceutical Announces the Appointment of New Board Member
Gerald Bagg brings deep understanding of CPG to CUREOXNARD, Calif., Aug. 02, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of directors. This...
CURE Pharmaceutical Announces Teleconference With Investors
Updates on Recent Transaction and Business will be Provided OXNARD, Calif., Aug. 01, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced that the Company will be hosting a teleconference...
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
Proceeds Will Be Used to Grow CURE's Wellness and Beauty Brands and Its Remaining Proprietary Platform TechnologyOXNARD, Calif., July 28, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) ("CURE"), a proprietary platform technology company, today announced that it...
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)
CURE's Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD)CCHMC to Seek Formulary...
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
LOS ANGELES, April 14, 2022 -- Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs...
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
COFEPRIS (Mexico's equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE's Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE's patented Oral Thin Film (OTF) dose form CUREform™OXNARD,...
Management Team
Board of Directors
Key Contacts
Investor Relations
(805) 410-9962 ext. 4
investor@curepharma.com
Transfer Agent
Continental Stock Transfer & Trust
1 State Street 30th Floor
New York, NY 10004-1561
www.continentalstock.com
Auditors
RBSM, LLP
805 3rd Avenue #1430
New York, NY 10022
Corporate Counsel
Stradling Yocca Carlson & Rauth
660 Newport Center Drive
Suite 1600
Newport Beach, CA 92660
T: 949-725-4000
F: 949-725-4100